Takeda Pharmaceutical Co. Ltd. has obtained FDA clearance to market Velcade -- acquired through its $8.8 billion takeover of Millennium Pharmaceuticals in May -- as an initial treatment for patients with multiple myeloma. The additional approval is based on study results showing that Velcade helped 35% of people newly diagnosed with the blood cancer experience remission.

Full Story:

Related Summaries